

# Alloimmunity & Trauma

*Team Pham*

*19 November, 2018*

## Contents

Tables . . . . .	1
Table 4: Outcomes analysis . . . . .	1
Supplemental Figure 1: Antibody Frequency by Gender . . . . .	1
Supplemental Figure 2: Antibody Frequency by Race . . . . .	1

## Tables

**Table 4: Outcomes analysis**

**Supplemental Figure 1: Antibody Frequency by Gender**

**Supplemental Figure 2: Antibody Frequency by Race**

Table 1: Demographics

	Anti- (n = 4116)	Anti+ (n = 66)	$p^a$
age (mean (sd))	47.30 (19.11)	48.32 (20.74)	0.669
gender = M (%)	2933 (71.3)	42 (63.6)	0.223
race = Other (%)	2896 (70.4)	47 (71.2)	0.988
death = 1 (%)	469 (11.4)	13 (19.7)	0.057
los (median [IQR])	11.66 [6.00, 22.58]	38.16 [24.50, 60.10]	<0.001
RBCtrans (median [IQR])	2.00 [0.00, 6.00]	16.50 [9.00, 29.00]	<0.001
plasmatrans (median [IQR])	0.00 [0.00, 2.00]	5.50 [1.00, 21.00]	<0.001
cryop (median [IQR])	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	NaN
pp (median [IQR])	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	NaN
ntest (median [IQR])	2.00 [1.00, 3.00]	7.00 [4.25, 11.75]	<0.001

Table 2: Antibody Specificity

antibody	Frequency
A1	1
C	2
D	7
E	15
Fya	1
Jka	6
Lea	4
Leb	1
M	3
NSE	28
S	1

Table 3: Transfusion and Antibody Development

Number of RBC transfusion	% Developed Antibody During Encounter
0	0.0637349
1-5	0.5899705
6-10	1.9017433
11-20	4.9095607
>20	10.8786611